Scientists Release Data Backing Hepatitis B Vaccines for Newborns Ahead of Crucial Vaccine Panel Vote
Scientists Release Data Backing Hepatitis B Vaccines for Newborns Ahead of Crucial Vaccine Panel Vote
The review was carried out and released by the Vaccine Integrity Project, which is dedicated to bolstering vaccines in the U.S.
A group of vaccine scientists on Tuesday released a report that staunchly supports giving the hepatitis B vaccine to newborns. The review, which included data from more than 400 studies and other reports, found that the vaccine has slashed infections in children by more than 95 percent.
“The totality of evidence—epidemiologic, clinical, and operational—supports maintaining universal hepatitis B vaccination within 24 hours of birth for all medically stable infants,” the authors concluded in a public comment about the report.
Hepatitis B is a liver disease caused by the hepatitis virus and spread through bodily fluids. Chronic infections can cause liver cancer, and the infection can be fatal.
On supporting science journalism
If you’re enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
The release comes days ahead of a vote on whether to change the guidance on the hep B shot for newborns slated for later this week by the U.S. Centers for Disease Control and Prevention’s vaccine advisory panel. The Advisory Committee on Immunization Practices has informed CDC policy for years; earlier this year, the 17-person committee was fired and restocked with health secretary and noted vaccine skeptic Robert F. Kennedy, Jr.’s handpicked advisers, many of whom have also expressed doubts over well-established vaccines.
The vaccine panel is widely expected to vote to shift the timing of the vaccine from birth until later in childhood, but experts have said that the delay will endanger children. A separate preprint modeling study posted to medRxiv on November 25 found that if the vaccine were to be delayed by just two months, some 1,400 babies would become chronically infected with hepatitis B.
“Delaying the first dose would reduce protection for infants and increase the risk of avoidable [hep B] infections, undermining decades of progress in hepatitis B prevention and U.S. efforts to eliminate viral hepatitis as a public health threat,” the report authors wrote in their public comment.
It’s Time to Stand Up for Science
If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.
I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.
If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.
In return, you get essential news, captivating podcasts, brilliant infographics, can’t-miss newsletters, must-watch videos, challenging games, and the science world’s best writing and reporting. You can even gift someone a subscription.
There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.
Source link
